biostudies-literaturePistorius KWellcome Trust103974https://www.ebi.ac.uk/biostudies/studies/S-EPMC9038546biostudies-literatureUnknown79<h4>Background</h4>Rheumatoid arthritis (RA) is a progressive degenerative disorder that leads to joint destruction. Available treatments only target the inflammatory component with minimal impact on joint repair. We recently uncovered a previously unappreciated family of pro-resolving mediators, the maresin conjugate in tissue regeneration (MCTR), that display both immunoregulatory and tissue-protective activities. Thus, we queried whether the production of these autacoids is disrupted in RA patients and whether they can be useful in treating joint inflammation and promoting joint repair.<h4>Methods</h4>Using a highly phenotyped RA cohort we evaluated plasma MCTR concentrations and correlated these to clinical markers of disease activity. To evaluate the immunoregulatory and tissue reparaEBioMedicineMCTR3 reprograms arthritic monocytes to upregulate Arginase-1 and exert pro-resolving and tissue-protective functions in experimental arthritis.PMC9038546107613/Z/15/ZSouza PRDalli JPitsillides AGomez EAPistorius KKoenis DSRajeeve VSpur BWFoster JRodriguez ARSosabowski JPitzalis CHopkinson MLy LfalseMCTR3 reprograms arthritic monocytes to upregulate Arginase-1 and exert pro-resolving and tissue-protective functions in experimental arthritis.<h4>Background</h4>Rheumatoid arthritis (RA) is a progressive degenerative disorder that leads to joint destruction. Available treatments only target the inflammatory component with minimal impact on joint repair. We recently uncovered a previously unappreciated family of pro-resolving mediators, the maresin conjugate in tissue regeneration (MCTR), that display both immunoregulatory and tissue-protective activities. Thus, we queried whether the production of these autacoids is disrupted in RA patients and whether they can be useful in treating joint inflammation and promoting joint repair.<h4>Methods</h4>Using a highly phenotyped RA cohort we evaluated plasma MCTR concentrations and correlated these to clinical markers of disease activity. To evaluate the immunoregulatory and tissue repara2022-01-01T00:00:00Z2022 May2025-04-22T18:26:25.674Z2025-02-19T01:23:30.119ZS-EPMC90385463543045310.1016/j.ebiom.2022.103974